This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 Apr 2012

Cara Therapeutics Completes Phase-I Study of Oral CR845

Cara Therapeutics has announced that phase-I trial results have provided a basis for further clinical development of its oral formulation of CR845.

Cara Therapeutics has completed its first phase-I clinical trial with an oral formulation of CR845, a peptide-based, peripherally-restricted kappa opioid receptor agonist.


An intravenous (IV) formulation of CR845 is currently being developed for the treatment of acute post-operative pain and it is hoped that an oral version can also be commercialised to treat ongoing pain following discharge from hospital.


The single-centre phase-I study aimed to assess the pharmacokinetics, safety and pharmacodynamics of CR845 in 50 healthy male volunteers.


Participants received one of four single ascending doses of orally available CR845 or a placebo.


Related News